Amicus Therapeutics Inc (FOLD.OQ)

FOLD.OQ on NASDAQ Stock Exchange Global Market

8.13USD
26 Nov 2014
Price Change (% chg)

$0.18 (+2.26%)
Prev Close
$7.95
Open
$7.82
Day's High
$8.34
Day's Low
$7.75
Volume
501,979
Avg. Vol
424,350
52-wk High
$8.34
52-wk Low
$1.76

FOLD.OQ

Chart for FOLD.OQ

About

Amicus Therapeutics, Inc. (Amicus) is a United States-based biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule drugs known as pharmacological chaperones for treating a range of diseases, including lysosomal storage diseases and diseases of neurodegeneratio... (more)

Overall

Beta: 1.73
Market Cap (Mil.): $756.96
Shares Outstanding (Mil.): 93.11
Dividend: --
Yield (%): --

Financials

  FOLD.OQ Industry Sector
P/E (TTM): -- 37.83 38.74
EPS (TTM): -0.90 -- --
ROI: -69.63 17.93 17.27
ROE: -171.84 18.73 18.18
Search Stocks

Amicus lead drug nears approval as late-stage trial succeeds

- Amicus Therapeutics Inc is a step closer to bringing its first drug to the market after trial data paved the way for its lead drug to become the first oral treatment for patients with a disorder that causes an abnormal build-up of fat.

20 Aug 2014

UPDATE 3-Amicus lead drug nears approval as late-stage trial succeeds

* Migalastat as effective as standard therapies for Fabry disease

20 Aug 2014

Amicus's fat accumulation drug effective in second late-stage study

Aug 20 - Amicus Therapeutics Inc said its experimental drug was as effective as enzyme replacement therapies (ERTs) after 18 months in patients with an inherited disorder that leads to the abnormal build-up of fat.

20 Aug 2014

Competitors

  Price Change
Sanofi SA (SASY.PA) €76.70 +0.27
Shire PLC (SHP.L) 4,530.00p +17.00
Shire PLC (3159084.L) -- --
Actelion Ltd (ATLN.VX) CHF112.90 +0.60
Protalix BioTherapeutics Inc. (PLX.TA) 809.00₪ +4.50

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks